Impax confirms challenge of patent relating to RENVELA

NewsGuard 100/100 Score

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation ("Genzyme") in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.

Impax filed its Abbreviated New Drug Application ("ANDA") containing a paragraph IV certification for a generic version of RENVELA® with the U.S. Food & Drug Administration ("FDA"). Following receipt of the notice from the FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner of its paragraph IV certification.

On July 1, 2010, Genzyme filed suit for patent infringement against Impax in the United States District Court for the District of Maryland. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, will commercialize the products.

RENVELA® is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease on dialysis. According to Wolters Kluwer Health, U.S. sales of RENVELA®, 2.4 g and 0.8 g (for suspension), were approximately $6.8 million for the past seven months ending April 2010.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.